Price (GBX)
443.00 3.87% (16.50)
Track 1 instrument
Open / Last close
- / 426.50
High / Low
444.50 / 425.50
Bid / Offer
442.50 / 443.50
Special Condition: -
Trading Status: Regular Trading
As at 23.09.20 13:09:20 - All data delayed at least 15 minutes

Polypipe Group PLC instruments

Select instrument to view
Equity (1)
Code Instrument name Price Change Type Documentation
PLPORD GBP0.001443.00

Price information

What's this?
Open price
Previous close price / date
426.50 / 22 September 2020
52 week range
381.00 / 619.00
YTD return
1 year return

Instrument information

What's this?
Main Market
Instrument market cap (£m)
Earnings per share
Issue date
11 April 2014
Market identifier code (MIC)
Country of share register
Market segment
Trading service
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
23.09.20 13:08:31 443.00 GBX 62 274.66 AT ALGO XLON
23.09.20 13:06:31 443.75 GBX 309 1,371.19 Off-Book NLIQ XLON
23.09.20 13:06:31 443.75 GBX 2,028 8,999.25 Off-Book NLIQ XLON
23.09.20 13:06:31 443.75 GBX 199 883.06 Off-Book NLIQ XLON
23.09.20 13:02:50 443.11 GBX 2,000 8,862.10 Off-Book - XLON

Equity Research

from Polypipe Group PLC
Polypipe - In cautious recovery mode

Polypipe remains a strategically well-placed business with leading positions in its building materials market segments supported by long-term drivers. Actions taken – including the £120m equity raise in May – will aid the company’s ability to absorb the disruptive effects ...

View report
Polypipe - Well-placed but revenue progress moderates

Approaching the year end, slower trading in certain sub-sectors causes us to trim our FY19 earnings estimates by 5% (with more modest adjustments thereafter). This does not change our view that the company is well placed by sector to benefit from some long-term structural drivers in the building ...

View report
Polypipe - Clear fit from bolt-on deal

The highly complementary £14m acquisition of Alderburgh expands Polypipe’s stormwater management portfolio offering, adding design and installation capabilities also. The earnings impact is modest but this serves as a further strengthening of Polypipe’s market position in the re ...

View report
Polypipe - Premium positioning

Polypipe’s rating is currently slightly ahead of its sector, but this overlooks the company’s positioning in long-term growth segments, in our view. The FY18 trading performance was noticeably stronger in H2, though margin progression was constrained by short-term production inefficie ...

View report
Morning Song

Gooch & Housego (GHH LN) PBT up 6%, EPS up 4-5% on acquisition of ITL | Polypipe Group (PLP LN) Full year guidance reiterated in today’s interims | Realm Therapeutics (RLM LN) In-line H1s overshadowed by negative Phase II AD trial result

View report
Issuer presentations live and on demand
Watch on Spark Live